91 related articles for article (PubMed ID: 8827087)
1. The antiangiogenic agent linomide inhibits tumor necrosis factor-alpha secretion via inhibition of its synthesis.
Joseph IB; Isaacs JT
Prostate; 1996 Sep; 29(3):183-90. PubMed ID: 8827087
[TBL] [Abstract][Full Text] [Related]
2. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers.
Vukanovic J; Isaacs JT
Cancer Res; 1995 Apr; 55(7):1499-504. PubMed ID: 7533663
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
4. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide.
Vukanovic J; Isaacs JT
Cancer Res; 1995 Aug; 55(16):3517-20. PubMed ID: 7543015
[TBL] [Abstract][Full Text] [Related]
5. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers.
Ichikawa T; Lamb JC; Christensson PI; Hartley-Asp B; Isaacs JT
Cancer Res; 1992 Jun; 52(11):3022-8. PubMed ID: 1591718
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic effects of the quinoline-3-carboxamide linomide.
Vukanovic J; Passaniti A; Hirata T; Traystman RJ; Hartley-Asp B; Isaacs JT
Cancer Res; 1993 Apr; 53(8):1833-7. PubMed ID: 7682157
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of linomide on lipopolysaccharide-induced proinflammatory cytokine tumor necrosis factor-alpha production in RAW264.7 macrophages through suppression of NF-kappaB, p38, and JNK activation.
Xiao ZY; Zhou WX; Zhang YX; Cheng JP; He JF; Yang RF; Yun LH
Immunol Lett; 2007 Dec; 114(2):81-5. PubMed ID: 17964662
[TBL] [Abstract][Full Text] [Related]
8. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents.
Joseph IB; Isaacs JT
J Natl Cancer Inst; 1998 Nov; 90(21):1648-53. PubMed ID: 9811314
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers.
Vukanovic J; Hartley-Asp B; Isaacs JT
Prostate; 1995 May; 26(5):235-46. PubMed ID: 7538663
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents.
Joseph IB; Vukanovic J; Isaacs JT
Cancer Res; 1996 Aug; 56(15):3404-8. PubMed ID: 8758902
[TBL] [Abstract][Full Text] [Related]
11. Linomide abolishes leukocyte adhesion and extravascular recruitment induced by tumor necrosis factor alpha in vivo.
Zhang XW; Hedlund G; Borgström P; Arfors KE; Thorlacius H
J Leukoc Biol; 2000 Nov; 68(5):621-6. PubMed ID: 11073099
[TBL] [Abstract][Full Text] [Related]
12. Effect of Linomide on adhesion molecules, TNF-alpha, nitrogen oxide, and cell adhesion.
Abdul-Hai A; Hershkoviz R; Weiss L; Lider O; Slavin S
Int Immunopharmacol; 2005 Feb; 5(2):231-9. PubMed ID: 15652754
[TBL] [Abstract][Full Text] [Related]
13. Anti-lipopolysaccharide monoclonal antibodies inhibit macrophage TNF messenger RNA synthesis in vitro.
Battafarano RJ; Burd RS; Cody CS; Kellogg TA; Raymond CS; Ratz CA; Dunn DL
J Surg Res; 1993 Apr; 54(4):342-8. PubMed ID: 8331928
[TBL] [Abstract][Full Text] [Related]
14. Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages.
Jeong JY; Jue DM
J Immunol; 1997 May; 158(10):4901-7. PubMed ID: 9144507
[TBL] [Abstract][Full Text] [Related]
15. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M
Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
[TBL] [Abstract][Full Text] [Related]
16. Activation of the adenosine A3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2.
Martin L; Pingle SC; Hallam DM; Rybak LP; Ramkumar V
J Pharmacol Exp Ther; 2006 Jan; 316(1):71-8. PubMed ID: 16188954
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin-dependent autocrine secretion of tumor necrosis factor-alpha in hematopoietic cells modulates proliferation via MAP kinase--ERK-1/2 and does not require tyrosine docking sites in the EPO receptor.
Chen J; Jacobs-Helber SM; Barber DL; Sawyer ST
Exp Cell Res; 2004 Aug; 298(1):155-66. PubMed ID: 15242770
[TBL] [Abstract][Full Text] [Related]
18. [Effects of RNA interference on expression of tumor necrosis factor-alpha in lipopolysaccharide-activated mouse macrophages].
Tan B; Li YY; Nie YQ; DU YL
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(30):2140-3. PubMed ID: 17988537
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of angiogenesis and metastases of the Lewis-lung cell carcinoma by the quinoline-3-carboxamide, Linomide.
Borgström P; Torres Filho IP; Hartley-Asp B
Anticancer Res; 1995; 15(3):719-28. PubMed ID: 7544090
[TBL] [Abstract][Full Text] [Related]
20. (+)-Catechin inhibits tumour angiogenesis and regulates the production of nitric oxide and TNF-alpha in LPS-stimulated macrophages.
Guruvayoorappan C; Kuttan G
Innate Immun; 2008 Jun; 14(3):160-74. PubMed ID: 18562575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
